CAMBRIDGE, Mass., Dec. 16 /PRNewswire/ -- Fuld & Company today announced that Wayne Rosenkrans, Ph.D., will join the Company as vice president consulting, specializing in strategic gaming for the pharmaceutical and healthcare industries.
"We are excited to have Dr. Rosenkrans join the Fuld team," said Leonard Fuld, president. "His extensive accomplishment in the global pharmaceutical industry; government and academia -- coupled with his involvement on the cutting edge of personalized medicine -- makes him an extraordinary asset for our clients."
Fuld & Company's Pharmaceuticals Practice provides all levels of competitive support from research to consulting. The firm has serviced over 100 biotech, pharmaceutical and diagnostics/device companies for training, custom research, and systems consulting needs. Fuld assesses new product progress from early-stage development to product launch, technology partnerships between biotech and big pharma, as well as changing global technologies, regulations, and markets. The firm has researched over 60 different therapeutic categories worldwide.
Rosenkrans is a Distinguished Fellow at the Center for Biomedical Innovation at MIT working on healthcare strategy and policy issues related to science and medicine. He is also Chairman, President and a member of the board of directors of the Personalized Medicine Coalition, a Washington DC-based organization working with government and other agencies on evolving healthcare policy for Personalized Healthcare. He is also Chief Applications Officer for SciTech Strategies, focusing on scientific competency and capacity development for academia and industry.
Previously, Rosenkrans served as Director of External Relations for the Personalized Healthcare Team and Evidence-based Medicine (EBM) at AstraZeneca where he had responsibility for long-range external relations strategy and policy
'/>"/>
SOURCE Fuld & Company Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate2.
Myngle Best ICT Company at the European Ventures Summit3.
SCRIP, the Leading Pharmaceutical Magazine in the World Crowns Glenmark as the "Best Pharma Company in the World - SME" and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London4.
ProMetic signs $35 M Long-term Supply Agreement with European Biopharmaceutical company5.
CBDM.T, the Market and Business Intelligence Company Reviews the Biofuel Market 6.
The Female Health Company Reports Record Results for Fiscal Year 2008, at High End of Guidance7.
CBDM.T, the Market and Business Intelligence Company Reviews the Biofuel Market8.
Laureate Pharma Honored as Emerging Life Sciences Company of the Year9.
Michigan Company Founded upon What Could Be History's Most Important Breakthrough in AI and Robotics10.
Genoptix Ranked Ninth Fastest-Growing Company in North America on Deloittes 2008 Technology Fast 50011.
West Michigans Newest Medical Device Company Receives Support from the West Michigan Science & Technology Initiative and EDF Ventures